AstraZeneca PLC (AZN.LN) said Wednesday that a phase 3 trial of its Breztri Aerosphere treatment of chronic obstructive pulmonary disease had met its primary objective.
The pharmaceutical company said that in the Ethos trial, Breztri Aerosphere showed a statistically significant reduction in symptoms when compared with the standard recommended therapies for COPD.
Breztri Aerosphere is a combination of three different drugs and was being compared to dual-combination therapies.
The treatment has been approved in Japan, and is under review in China, the U.S. and Europe.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.